elafibranor

Genfit abandons late-stage trial of NASH drug elafibranor
Genfit abandons late-stage trial of NASH drug elafibranor
Pharmaforum
Genfit
elafibranor
NASH
clinical trials
Flag link:
Biotech Genfit warns costs of failed NASH trial will drag deep into 2020
Biotech Genfit warns costs of failed NASH trial will drag deep into 2020
Fierce Biotech
Genfit
NASH
clinical trials
elafibranor
Flag link:
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study
Xconomy
Genfit
clinical trials
NASH
elafibranor
Flag link:
The crucial data readouts coming soon for small biotechs
The crucial data readouts coming soon for small biotechs
EP Vantage
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Flag link:
COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout
COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout
Fierce Biotech
Genfit
NASH
clinical trials
COVID-19
elafibranor
Flag link:
Genfit's NASH key phase 3 data delayed
Genfit's NASH key phase 3 data delayed
Fierce Biotech
Genfit
NASH
clinical trials
elafibranor
Flag link:
As NASH shifts again, the focus remains on Genfit’s big readout
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Flag link:
Genfit’s liver disease Hail Mary approaches
Genfit’s liver disease Hail Mary approaches
EP Vantage
Genfit
NASH
elafibranor
Flag link:
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
BioSpace
Genfit
breakthrough therapy
FDA
primary biliary cholangitis
elafibranor
Flag link:
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Fierce Biotech
Genfit
FDA
primary biliary cholangitis
elafibranor
clinical trials
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
Flag link:
GENFIT Receives Positive Safety Review for NASH Candidate Elafibranor
GENFIT Receives Positive Safety Review for NASH Candidate Elafibranor
CP Wire
Genfit
NASH
elafibranor
Flag link:
Genfit launches a PhIII study for NASH drug
Genfit launches a PhIII study for NASH drug
Fierce Biotech
Genmit
NASH
elafibranor
clinical trials
Flag link: